OverviewChartTechnicalNewsTraderScreen

Supernus Pharmaceuticals Inc/  US8684591089  /

NASDAQ
7/29/2024  4:07:03 PM Chg. 0.0000 Volume Bid4:07:03 PM Ask4:07:03 PM High Low
30.7500USD 0.00% 24,820
Turnover: 597,583.2134		 30.7500Bid Size: 200 30.9200Ask Size: 400 30.9300 30.4400
GlobeNewswire 5/30 Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire 5/23 Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epile...
GlobeNewswire 5/21 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire 5/12 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire 5/9 Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa St...
GlobeNewswire 5/8 Supernus Announces First Quarter 2024 Financial Results
GlobeNewswire 5/2 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire 5/1 Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
GlobeNewswire 4/24 Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call o...
GlobeNewswire 4/24 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire 4/8 Supernus Provides Regulatory Update for SPN-830
GlobeNewswire 3/26 MannKind Announces CFO Transition
GlobeNewswire 3/6 Supernus to Participate in Two Upcoming Investor Conferences
GlobeNewswire 2/28 Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
GlobeNewswire 2/27 Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 2/13 Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Co...
GlobeNewswire 2/5 Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
GlobeNewswire 2/2 SAB Biotherapeutics Announces Executive Leadership Change
GlobeNewswire 11/8/2023 Supernus Announces Third Quarter 2023 Financial Results
GlobeNewswire 11/7/2023 Supernus to Participate in the Jefferies London Healthcare Conference
GlobeNewswire 11/2/2023 Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
GlobeNewswire 10/25/2023 Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call o...
GlobeNewswire 10/16/2023 Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journe...
GlobeNewswire 10/10/2023 Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
GlobeNewswire 10/9/2023 Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device